XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Stock Options and Restricted Stock Awards
6 Months Ended
Jun. 30, 2020
Stock Options and Restricted Stock Awards  
Stock Options and Restricted Stock Awards

Note 11: Stock Options and Restricted Stock Awards

The Company established the Bridgewater Bancshares, Inc. 2012 Combined Incentive and Non-Statutory Stock Option Plan (the “2012 Plan”) under which the Company may grant options to its directors, officers, employees, and consultants for up to 750,000 shares of common stock. Both incentive stock options and nonqualified stock options may be granted under the 2012 Plan. The exercise price of each option equals the fair market value of the Company’s stock on the date of grant and the maximum term of each outstanding option is ten years. All outstanding options have been granted with vesting periods of five years. As of June 30, 2020 and December 31, 2019, there were no remaining shares of the Company’s common stock reserved for future option grants under the 2012 Plan.

In 2017, the Company adopted the Bridgewater Bancshares, Inc. 2017 Combined Incentive and Non-Statutory Stock Option Plan (the “2017 Plan”). Under the 2017 Plan, the Company may grant options to its directors, officers, employees and consultants for up to 1,500,000 shares of common stock. Both incentive stock options and nonqualified stock options may be granted under the 2017 Plan. The exercise price of each option equals the fair market value of the Company’s stock on the date of grant and the maximum term of each outstanding option is ten years. All outstanding options have been granted with vesting periods of four or five years. As of June 30, 2020 and December 31, 2019, there were 310,600 remaining shares of the Company’s common stock reserved for future option grants under the 2017 Plan.

In 2019, the Company adopted the Bridgewater Bancshares, Inc. 2019 Equity Incentive Plan (the “2019 EIP”). The types of awards which may be granted under the 2019 EIP include incentive and nonqualified stock options, stock appreciation rights, stock awards, restricted stock units, restricted stock and cash incentive awards. The Company may grant these awards to its directors, officers, employees and certain other service providers for up to 1,000,000 shares of common stock. The exercise price of each option equals the fair market value of the Company’s stock on the date of grant and the maximum term of each award is ten years. All outstanding awards have been granted with a vesting period of four years. As of June 30, 2020 and December 31, 2019, there were 780,688 and 867,040 of remaining shares of the Company’s common stock reserved for future grants under the 2019 EIP.

Stock Options

The fair value of each option award is estimated on the date of grant using a closed form option valuation (Black-Scholes) model that uses the assumptions noted in the table below. Expected volatilities are based on an industry index as described below. The expected term of options granted is based on historical data and represents the period of time that options granted are expected to be outstanding, which takes into account that the options are not transferable. The risk-free interest rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. Historically, the Company has not paid a dividend on its common stock and does not expect to do so in the near future.

The Company used the S&P 600 CM Bank Index as its historical volatility index. The S&P 600 CM Bank Index is an index of publicly traded small capitalization, regional, commercial banks located throughout the United States. There were 54 banks in the index ranging in market capitalization from $500 million up to $4.5 billion.

The weighted average assumptions used in the model for valuing stock option grants for the six months ended June 30, 2020, are as follows:

June 30, 

    

2020

    

Dividend Yield

 

%  

Expected Life

 

7

Years

Expected Volatility

 

44.14

%  

Risk-Free Interest Rate

 

0.68

%  

The following table presents a summary of the status of the Company’s stock option grants for the six months ended June 30, 2020:

June 30, 2020

    

    

    

Weighted

Average

Shares

Exercise Price

Outstanding at Beginning of Year

 

1,961,650

$

7.08

Granted

 

60,000

 

10.61

Exercised

 

(15,500)

 

2.55

Forfeitures

 

 

Outstanding at Period End

 

2,006,150

$

7.22

Options Exercisable at Period End

 

993,550

$

5.09

For the three months ended June 30, 2020 and 2019, the Company recognized compensation expense for stock options of $230 and $174, respectively. For the six months ended June 30, 2020 and 2019, the Company recognized compensation expense for stock options of $448 and $348, respectively.

The following table presents information pertaining to options outstanding at June 30, 2020:

Options Outstanding

Options Exercisable

Number

Remaining

    

Number

Exercise Price

    

Outstanding

    

Contractual Life

Exercise Price

    

Outstanding

$

2.13

 

66,750

 

2.8

Years  

$

2.13

 

66,750

3.00

 

447,500

 

3.5

Years  

 

3.00

 

447,500

3.58

 

45,000

 

4.5

Years  

 

3.58

 

45,000

7.47

 

1,023,900

 

7.3

Years  

 

7.47

 

402,300

13.22

25,000

7.9

Years  

13.22

10,000

12.86

45,000

8.2

Years  

12.86

9,000

12.94

30,000

8.3

Years  

12.94

6,000

11.59

25,000

8.3

Years  

11.59

5,000

11.15

10,000

8.7

Years  

11.15

2,000

11.13

50,000

9.2

Years  

11.13

12.92

178,000

9.4

Years  

12.92

12.67

25,000

9.7

Years  

12.67

8.76

25,000

9.8

Years  

8.76

10.08

10,000

9.9

Years  

10.08

Totals

 

2,006,150

 

6.6

Years  

$

7.22

993,550

As of June 30, 2020, there was $2,553 of total unrecognized compensation cost related to nonvested stock options granted under the 2012 Plan, 2017 Plan and 2019 EIP that is expected to be recognized over a weighted-average period of 4.8 years.

The following presents an analysis of nonvested stock options issued and outstanding for the six months ended June 30, 2020:

    

    

    

Weighted

Number of

Average Grant

Shares

Date Fair Value

Nonvested Options at December 31, 2019

 

969,600

$

3.08

Granted

 

60,000

4.39

Vested

 

(17,000)

2.61

Forfeited

 

Nonvested Options at June 30, 2020

 

1,012,600

$

3.16

Restricted Stock Awards

In 2019, the Company began granting restricted stock awards out of the 2019 EIP. These awards vest in equal annual installments on the first four anniversaries of the date of the grant. Nonvested restricted stock awards are classified as outstanding shares with voting and forfeitable dividend rights.

The following table presents an analysis of nonvested restricted stock awards outstanding for the six months ended June 30, 2020:

    

    

    

Weighted

Number of

Average Grant

Shares

Date Fair Value

Nonvested Awards at December 31, 2019

 

132,960

$

12.92

Granted

 

11,141

10.32

Vested

 

Forfeited

Nonvested Awards at June 30, 2020

 

144,101

$

12.72

Compensation expense associated with the restricted stock awards is recognized on a straight-line basis over the period that the restrictions associated with the awards lapse based on the total cost of the award at the grant date. For the three and six months ended June 30, 2020, the Company recognized compensation expense for restricted stock awards of $113 and $221, respectively. No compensation expense was recognized for restricted stock awards for the three and six months ended June 30, 2019.

As of June 30, 2020, there was $1,582 of total unrecognized compensation cost related to nonvested restricted stock awards granted under the 2019 EIP that is expected to be recognized over a period of four years.

In addition, during the six months ended June 30, 2020, the Company issued 15,211 shares of common stock to directors as a part of their compensation for their annual services on the Company’s board of directors. The aggregate value of the shares issued to directors of $152 is included in stock based compensation expense in the accompanying consolidated statements of shareholders’ equity.